RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 CKT Implicated in Worse Outcomes With Ibrutinib Therapy of CLL
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 16
OP 17
DO 10.1177/1559897715570606
UL http://mdc.sagepub.com/content/14/55/16.2.abstract
AB The outcome of patients with chronic lymphocytic leukemia treated with ibrutinib-based regimens indicates that complex metaphase karyotype is a more important predictor of outcome than del(17p). Lack of complex karyotype is associated with less-frequent disease progression. Patients with complex karyotype may be an ideal group in which to study novel treatments.